| Returns | 1W : -0.1% , 1M : 6%,1Y : 16.7% |
| LT : |
Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : Low |
| ST : |
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
| Peers & Returns | 1W | 1M | 1Y |
| TTK HEALTHCARE LTD | -0.1% | 6% | 16.7% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 0.4% | 7% | 51.4% |
| DR REDDYS LABORATORIES LTD | -4.4% | -8.8% | 40% |
| DIVIS LABORATORIES LTD | -2.5% | -1.3% | 61.2% |
| CIPLA LTD | 0.2% | -3.9% | 83.5% |
| BIOCON LTD | -1.5% | 5.4% | 24.1% |
| AUROBINDO PHARMA LTD | -2.9% | -10% | 71.1% |
| LUPIN LTD | 0.2% | -4.7% | 49.7% |
| TORRENT PHARMACEUTICALS LTD | -1.3% | -6.9% | 14% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
65.17
P/E Calculated based on EPS of 8.72
[ Mar2020 - Standalone Results ] 3.28
P/B Calculated based on Book Value of 173.09
[ Mar2020 - Standalone Results ] 1.37
P/S Calculated based on Revenues of 583.575 Cr
[ TTM - Standalone Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
70% -9% -1% |
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
